CA-GUPSHUP
20.12.2021 12:02:34 CET | Business Wire | Press release
Gupshup, the leader in conversational messaging, today announced the launch of a WhatsApp-based commerce solution that can enable any business to create a digital “storefront” on WhatsApp. Businesses can enable conversational journeys across every stage of the buying process: pre-purchase, purchase, and post-purchase. Based on WhatsApp’s recently launched commerce capability, Gupshup can help a business manage the complete buying experience on WhatsApp. With more than two billion active monthly users in 180 countries using WhatsApp, it is the ideal conversational commerce platform for businesses. This full-featured commerce solution also leverages Gupshup's recently launched 1-Click Bill Pay feature, which enables businesses to collect payments via WhatsApp and other messaging apps.
With Gupshup’s WhatsApp-based commerce solution, a business can create a product catalog on WhatsApp, converse with customers via AI-powered chatbots for product discovery, guide them through checkout and payment, and support them 24/7 with chatbots and live agents. New interactive elements such as multi-product messages make it simpler for businesses to showcase their offerings through the store’s catalog.
This enables businesses to present their offerings through structured experience with images and organized product details. Customers can also add preferred items to their carts on WhatsApp, interact with the businesses in real time, and make payment through Gupshup’s recently launched 1-Click Bill Pay link, all without leaving the chat window. Many businesses already leverage WhatsApp for pre-purchase and post-purchase journeys, and with the newly available Commerce features, they can now manage the entire buying journey for customers on the world’s most popular messaging app.
A few interesting facts about WhatsApp for Business1 :
- Over 175 million people message a business account on WhatsApp every day2
- 68 percent of users say WhatsApp is the easiest way of contacting a business3
- 71 percent feel more confident about a business after messaging on WhatsApp3
“Gupshup offers the most advanced, comprehensive, and easy-to-use conversational commerce platform,” said Gaurav Kachhawa, Chief Product Officer, Gupshup. “Our goal is to enable every business, large and small, to get started with commerce through WhatsApp quickly and easily as well as realize the full potential of this capability to transform their business.”
“As one of the earliest Solution Provider partners of WhatsApp, we have already helped thousands of businesses across the world go live on WhatsApp Business. Our knowledgeable sales and solutions teams, along with a network of global partners, help businesses accelerate their digital transformation,” explained Ravi Sundararajan, COO, Gupshup. “We are seeing strong demand for the new Commerce features, and the early results for businesses are promising. This is certainly going to revolutionize the way businesses conduct e-commerce.”
Explore Gupshup’s WhatsApp-based Commerce Solution
About Gupshup
Gupshup enables better customer engagement through conversational messaging. Gupshup is the leading conversational messaging platform, powering over 6 billion messages per month. Across verticals, thousands of large and small businesses in emerging markets use Gupshup to build conversational experiences across marketing, sales and support. Gupshup's carrier-grade platform provides a single messaging API for 30+ channels, a rich conversational experience-building tool kit for any use case and a network of emerging market partnerships across messaging channels, device manufacturers, ISVs and operators. With Gupshup, businesses have made conversations an integral part of their customer engagement success. Gupshup is present in India, LATAM, South East Asia, Middle East, Eastern Europe, Africa and the United States. Visit www.gupshup.io . Converse with the Gupshup bot.
- https://blog.whatsapp.com/two-billion-users-connecting-the-world-privately/?lang=en
- https://blog.whatsapp.com/shopping-payments-and-customer-service-on-whatsapp
- “Motivations and Mindsets in Messaging” by Sentient Decision Science (Facebook-commissioned study of 8,157 people who use Messenger, WhatsApp and/or Instagram Direct on a daily basis), ages 18+ in the US, UK, BR and IN, June 2018.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211220005093/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom